1700013D24Rik Inhibitors
Chemical inhibitors of 1700013D24Rik function by interfering with specific signaling pathways and enzymes that are essential for the protein's activity. Staurosporine acts by targeting protein kinase C, a pivotal enzyme in the signaling cascade that activates 1700013D24Rik, leading to inhibition due to the prevention of necessary phosphorylation events. Wortmannin and LY294002 are both inhibitors of phosphoinositide 3-kinases (PI3K), which are instrumental in the PI3K/AKT pathway, a route crucial for 1700013D24Rik activation. By blocking PI3K, these inhibitors prevent the formation of phosphatidylinositol (3,4,5)-trisphosphate (PIP3) and subsequent AKT activation, resulting in the inhibition of 1700013D24Rik. Rapamycin takes a different approach by inhibiting the mechanistic target of rapamycin (mTOR), which is central to cell growth and survival signaling pathways involving 1700013D24Rik. Inhibition of mTOR by rapamycin reduces the protein's activity by cutting off the signaling events that activate 1700013D24Rik.
Further inhibitory actions are taken by SB203580 and SP600125, which target p38 MAP kinase and c-Jun N-terminal kinase (JNK), respectively. SB203580 prevents the activation of 1700013D24Rik by inhibiting p38 MAP kinase, which is responsible for phosphorylating and activating the protein. SP600125 disrupts 1700013D24Rik's function by inhibiting JNK, therefore obstructing the signaling required for the protein's activity. PD98059 and U0126 both inhibit MEK1/2, thereby preventing the activation of ERK in the MAPK/ERK pathway, which is known to phosphorylate various targets including 1700013D24Rik. Dasatinib and PP2, both Src family kinase inhibitors, prevent the phosphorylation and subsequent activation of 1700013D24Rik by inhibiting the activity of Src family kinases. Y-27632 targets the Rho-associated protein kinase (ROCK), influencing the regulation of the actin cytoskeleton and thereby inhibiting the function of 1700013D24Rik. Lastly, palbociclib inhibits CDK4/6, which are kinases involved in cell cycle progression, and this inhibition can affect the role of 1700013D24Rik within the cell cycle. Each of these chemicals, through their targeted action, serves to inhibit the activation and function of 1700013D24Rik by interfering with the protein's regulatory mechanisms.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine inhibits protein kinase C, which is a key enzyme in the signaling pathways that the protein 1700013D24Rik is involved in. The inhibition of this kinase leads to the inhibition of 1700013D24Rik by preventing the phosphorylation events required for its activation. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin acts as an inhibitor of phosphoinositide 3-kinases (PI3K), which play a crucial role in the signaling pathways that activate 1700013D24Rik. By inhibiting PI3K, wortmannin prevents the formation of PIP3 and thus inhibits the activation of AKT, subsequently inhibiting 1700013D24Rik. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is another PI3K inhibitor, similar to wortmannin, that blocks the activation of the PI3K/AKT pathway. This results in a downstream inhibition of 1700013D24Rik due to the lack of necessary phosphorylation signals that would normally be transmitted via this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin inhibits the mechanistic target of rapamycin (mTOR), a crucial kinase in the signaling pathway that regulates cell growth and survival, pathways where 1700013D24Rik is involved. Inhibition of mTOR leads to a decrease in the protein's activity due to a reduction in the signaling events that would normally activate 1700013D24Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase, which is involved in the stress response and is a kinase that could be responsible for activating 1700013D24Rik. By inhibiting p38, SB203580 prevents the phosphorylation and activation of 1700013D24Rik. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 inhibits c-Jun N-terminal kinase (JNK), which is implicated in the signaling pathways that can activate 1700013D24Rik. By inhibiting JNK, SP600125 disrupts the signaling required for the proper function of 1700013D24Rik. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 selectively inhibits MEK1/2, which are upstream of ERK in the MAPK/ERK pathway. Since ERK can phosphorylate a wide range of downstream targets including 1700013D24Rik, inhibiting MEK prevents the activation of ERK and the subsequent phosphorylation and activation of 1700013D24Rik. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 is another MEK1/2 inhibitor that prevents the activation of the MAPK/ERK pathway, thus inhibiting the phosphorylation and activation of 1700013D24Rik by blocking the necessary upstream signals. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src family kinase inhibitor. Since Src kinases can phosphorylate and activate multiple downstream proteins, including 1700013D24Rik, inhibiting Src kinases with dasatinib would result in the inhibition of 1700013D24Rik's function. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is another Src family kinase inhibitor, which functions similarly to dasatinib. By inhibiting Src kinase activity, PP2 prevents the activation of 1700013D24Rik, inhibiting its function. | ||||||